The presentation, which was part of the Emerging Technology Moderated Poster session, unveiled the results of the ARX-04 trial for the first time. The study was conducted on 140 patients under age 40 who had received a short-stay in-patient or out-patient procedure.
The first reported data from the ARX-04 trial came back in September, and showed that 49 percent of the patients experience a reduction in mean pain intensity. This was compared to the baseline numbers of 6.19 to 3.17 on a 0-10 rating scaled. The pain reduction was experienced during the first two hours of the administration of the medication with a duration of 12 hours. Patients began experiencing relief from their pain as early as 15 minutes after being dosed.
Alerts Sign-up